Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.
dc.contributor.author | Fillmore, Nathanael | |
dc.contributor.author | Bell, Steven | |
dc.contributor.author | Shen, Ciyue | |
dc.contributor.author | Nguyen, Vinh | |
dc.contributor.author | La, Jennifer | |
dc.contributor.author | Dubreuil, Maureen | |
dc.contributor.author | Strymish, Judith | |
dc.contributor.author | Brophy, Mary | |
dc.contributor.author | Mehta, Gautam | |
dc.contributor.author | Wu, Hao | |
dc.contributor.author | Lieberman, Judy | |
dc.contributor.author | Do, Nhan | |
dc.contributor.author | Sander, Chris | |
dc.date.accessioned | 2021-11-05T00:30:28Z | |
dc.date.available | 2021-11-05T00:30:28Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | https://www.repository.cam.ac.uk/handle/1810/330303 | |
dc.description.abstract | Effective, low-cost therapeutics are needed to prevent and treat COVID-19. Severe COVID-19 disease is linked to excessive inflammation. Disulfiram is an approved oral drug used to treat alcohol use disorder that is a potent anti-inflammatory agent and an inhibitor of the viral proteases. We investigated the potential effects of disulfiram on SARS-CoV-2 infection and disease severity in an observational study using a large database of clinical records from the national US Veterans Affairs healthcare system. A multivariable Cox regression adjusted for demographic information and diagnosis of alcohol use disorder revealed a reduced risk of SARS-CoV-2 infection with disulfiram use at a hazard ratio of 0.66 (34% lower risk, 95% confidence interval 24-43%). There were no COVID-19 related deaths among the 188 SARS-CoV-2 positive patients treated with disulfiram, in contrast to 5-6 statistically expected deaths based on the untreated population (P = 0.03). Our epidemiological results suggest that disulfiram may contribute to the reduced incidence and severity of COVID-19. These results support carefully planned clinical trials to assess the potential therapeutic effects of disulfiram in COVID-19. | |
dc.language | eng | |
dc.publisher | Public Library of Science (PLoS) | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study. | |
dc.type | Article | |
prism.issueIdentifier | 10 | |
prism.publicationDate | 2021 | |
prism.publicationName | PLoS One | |
prism.startingPage | e0259061 | |
prism.volume | 16 | |
dc.identifier.doi | 10.17863/CAM.77747 | |
dcterms.dateAccepted | 2021-10-11 | |
rioxxterms.versionofrecord | 10.1371/journal.pone.0259061 | |
rioxxterms.version | VoR | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2021 | |
dc.contributor.orcid | Fillmore, Nathanael [0000-0002-8058-3423] | |
dc.contributor.orcid | Bell, Steven [0000-0001-6774-3149] | |
dc.contributor.orcid | Shen, Ciyue [0000-0002-5416-2481] | |
dc.contributor.orcid | La, Jennifer [0000-0003-2266-0221] | |
dc.contributor.orcid | Mehta, Gautam [0000-0002-5696-359X] | |
dc.contributor.orcid | Wu, Hao [0000-0002-7281-8579] | |
dc.contributor.orcid | Lieberman, Judy [0000-0002-6200-4715] | |
dc.contributor.orcid | Do, Nhan [0000-0001-6868-7011] | |
dc.contributor.orcid | Sander, Chris [0000-0001-6059-6270] | |
dc.identifier.eissn | 1932-6203 | |
rioxxterms.type | Journal Article/Review | |
cam.issuedOnline | 2021-10-28 |
Files in this item
This item appears in the following Collection(s)
-
Cambridge University Research Outputs
Research outputs of the University of Cambridge